- Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
- A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancerDing, K.; Liu, Y.; Song, Y.; Xu, D.; Li, J.; Wang, J.; Chen, X.; Lin, R.; Jiang, Y.; Zhang, Y.; Zhang, W.; Cheng, Y.; Wu, X.; Yuan, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trialChen, H.; Hu, Y.; Fan, Y.; Wu, G.; Cang, S.; Yang, Y.; Yang, N.; Ma, R.; Jing, G.; Liu, A.; Xu, X.; Tang, S.; Cheng, Y.; Yu, Y.; Wu, Y-L.
会议论文
Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
8阅读
